Close
Company Search
Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

MaxCyte (MXCT) Share News

1234567

IN BRIEF: MaxCyte chief scientific officer leaves firm

29th Jan 2024 17:56

MaxCyte Inc - Maryland, US-based provider of cell engineering platform technologies developing "next-generation cell therapeutics" - Announces departure of Cenk Sumen as chief scientific officer, but he will remain on advisory board. Read More

TRADING UPDATES: Esken's Southend Airport faces further allegations

23rd Jan 2024 18:39

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More

MaxCyte's strategic platform licences redeem otherwise modest results

9th Jan 2024 12:18

(Alliance News) - MaxCyte Inc on Tuesday said that promising returns from its strategic platform licence program had bolstered its quarterly revenue expectations. Read More

MaxCyte teams with Singapore-based Lion to support TCR-T cell work

3rd Jan 2024 14:04

(Alliance News) - MaxCyte Inc on Wednesday said it had signed a strategic platform licence with Lion TCR to promote the latter's T cell receptor-T cell pipeline. Read More

TRADING UPDATES: Technology Minerals identifies lithium at Knockeen

12th Dec 2023 15:56

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More

EARNINGS AND TRADING: Chapel Down hopes to make splash on AIM

9th Nov 2023 14:14

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

UK earnings, trading statements calendar - next 7 days

1st Nov 2023 15:44

Read More

AIM WINNERS & LOSERS: SDX Energy receives gas prepayment from Citic

5th Oct 2023 10:16

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday. Read More

MaxCyte shares fall as warns of sharp revenue drop, citing volatility

5th Oct 2023 10:08

(Alliance News) - MaxCyte Inc on Thursday said it expects revenue in the third quarter and for all of 2023 to fall from a year before, citing volatility in customer activity in the life science tools sector. Read More

MaxCyte shares fall as revenue plummets in first half, loss widens

10th Aug 2023 10:22

(Alliance News) - MaxCyte Inc on Thursday reported an increased loss in the first half of 2023, as revenue fell while costs increased. Read More

UK earnings, trading statements calendar - next 7 days

2nd Aug 2023 15:46

Read More

TRADING UPDATES: MaxCyte strikes deal; Barkby sells Workshop

1st Aug 2023 14:26

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More

MaxCyte inks deal with Vittoria Therapeutics for cellular therapies

10th Jul 2023 14:05

(Alliance News) - MaxCyte Inc on Monday said it signed a strategic platform licence with Vittoria Biotherapeutics to advance cellular therapies. Read More

MaxCyte inks strategic platform license with Lyell Immunopharma

6th Jul 2023 13:58

(Alliance News) - MaxCyte Inc on Thursday said it has signed a strategic platform license with Lyell Immunopharma Inc, a clinical stage T cell reprogramming company. Read More

MaxCyte revenue declines, operating loss widens as costs increase

11th May 2023 10:26

(Alliance News) - MaxCyte Inc on Thursday reported a widened operating loss in the first quarter of 2023 as revenue fell and costs were higher. Read More

IN BRIEF: MaxCyte signs strategic platform license with Walking Fish

4th May 2023 17:26

MaxCyte Inc - cell-engineering technology platform based in US state of Maryland - Signs a strategic platform license with Walking Fish Therapeutics Inc, a biotechnology company that is "rapidly advancing B cell-based therapeutics." Under the terms of the agreement, Walking Fish obtains non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation technology and ExPERT platform. In return, MaxCyte is entitled to receive platform licensing fees, clinical milestone payments and sales-based payments. Read More

UK earnings, trading statements calendar - next 7 days

3rd May 2023 14:50

Read More

IN BRIEF: MaxCyte Chair Richard Douglas buys USD350,000 in shares

30th Mar 2023 16:03

MaxCyte Inc - cell-engineering technology platform based in US state of Maryland - Non-Executive Chair Richard Douglas buys 80,000 shares at average USD4.32, worth USD345,480, on Wednesday. Now has 100,000 shares, a 0.1% stake. Read More

MaxCyte appoints new chief financial officer, effective immediately

28th Mar 2023 10:44

(Alliance News) - MaxCyte Inc on Tuesday said it appointed Douglas Swirsky as its new chief financial officer, effective immediately. Read More

MaxCyte revenue up as growth expected in 2023; net loss widens

16th Mar 2023 12:20

(Alliance News) - MaxCyte Inc on Thursday said revenue was up by a third in 2022, as it expects further growth in 2023. Read More

1234567
FTSE 100 Latest
Value8,809.74
Change53.53